Weill Cornell Precision Medicine Institute Awaiting CLIA Approval; Will Use Sequencing To Guide Cancer Care | GenomeWeb

Within a newly created Institute for Precision Medicine, clinicians from Weill Cornell Medical College and New York Presbyterian Hospital plan to use whole-genome and exome sequencing, as well as other genomic and genetic analyses, to inform individualized treatment for cancer patients.

Moving forward, the center will also use genomic data to guide care for other disease areas, according to its leader, Mark Rubin, a professor of pathology at Weill Cornell.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.